3,4-bis(4-methoxyphenyl)-5-hydroxyethylisoxazole

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3,4-bis(4-methoxyphenyl)-5-hydroxyethylisoxazole
• 英文别名: 5-(2-Hydroxyethyl)-3,4-bis(4-methoxyphenyl)isoxazole；2-[3,4-bis(4-methoxyphenyl)-1,2-oxazol-5-yl]ethanol
• 化学式: C₁₉H₁₉NO₄
• 分子量: 325.364
• InChiKey: IHJUPVGPRVDYAQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  64.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3,4-bis(4-methoxyphenyl)-5-hydroxyethylisoxazole 在 四丁基氟化铵 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 24.0h， 生成 3,4-bis(4-methoxyphenyl)-5-vinylisoxazole
  参考文献：
  名称：

  [EN] HETEROCYCLES AND THEIR RADIOLABELED ANALOGS USEFUL AS COX-1 SELECTIVE INHIBITORS
  [FR] HÉTÉROCYCLES ET LEURS ANALOGUES RADIOMARQUÉS UTILES EN TANT QU'INHIBITEURS SÉLECTIFS DE COX-1

  摘要：

  本发明涉及一种新型杂环化合物，这些化合物是环氧合酶-1（COX-1）的有效和选择性抑制剂，以及它们的放射标记衍生物，这些衍生物既可用作多种病理病变的诊疗药物。

  公开号：

  WO2014115020A1
• 作为产物：
  描述：

  [(4-甲氧苯基)次甲基]氮烷氧化 在 正丁基锂 、 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 3,4-bis(4-methoxyphenyl)-5-hydroxyethylisoxazole
  参考文献：
  名称：

  Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viability

  摘要：

  A set of novel diarylisoxazoles has been projected using mofezolac (1) as a lead compound to investigate structure-inhibitory activity relationships of new compounds and the cyclooxygenases (COXs) catalytic activity. Mofezolac was chosen because is the most potent and selective reversible COX-1 inhibitor [COX-1 IC50 = 0.0079 mu M and COX-2 IC50 > 50 mu M, with a selectivity index (SI) in favor of COX-1 higher than 6300]. Seventeen new compounds were synthesized in fair to good yields and evaluated for their COXs inhibitory activity and selectivity. Sls ranged between 1 and higher than 11903,4-Bis(4-methoxyphenyl)-5-vinylisoxazole (22) has the highest SI with COX-1 IC50 = 0.042 mu M and COX-2 IC50 > 50 mu M. 1 and 22 were superior to aspirin in inhibiting platelet aggregation (IC50 = 0.45, 0.63 and 1.11 mu M, respectively) in human platelet rich plasma (hPRP) assay. They did not induce blood coagulation and hemolysis, and are neither genotoxic nor mutagen. 1 and 22 slightly increase bortezomib cytotoxic effect on multiple myeloma (MM) cell lines (NCI-H929 and RPMI-8226) and affects MM cell cycle and apoptosis when co-administered with the proteasome inhibitor bortezomib, a drug clinically used to treat plasma cell neoplasms including MM. In addition, structure-based binding mode of 1 and 22, through Fingerprints for Ligands and Proteins (FLAG) calculation, allowed to explain the one order of magnitude difference between COX-1 IC50 values of the two compounds. Specifically, the higher inhibitory potency seems due to the formation of a H-bond between COX-1 S530 and the carboxyl, present in 1 and absent in 22. (C) 2018 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2018.12.029

文献信息

• Styrene derivatives and salts thereof
  申请人：Taiho Pharmaceutical Co., Ltd.

  公开号：US05478856A1

  公开（公告）日：1995-12-26

  A styrene derivative represented by the formula (1) or a salt thereof: ##STR1##

  公式（1）表示的苯乙烯衍生物或其盐：##STR1##
• [EN] HETEROCYCLES AND THEIR RADIOLABELED ANALOGS USEFUL AS COX-1 SELECTIVE INHIBITORS<br/>[FR] HÉTÉROCYCLES ET LEURS ANALOGUES RADIOMARQUÉS UTILES EN TANT QU'INHIBITEURS SÉLECTIFS DE COX-1
  申请人：UNIV BARI

  公开号：WO2014115020A1

  公开（公告）日：2014-07-31

  The present invention relates to novel heterocycles which are potent and selective inhibitors of cyclooxygenase-1 (COX-1) and to their radiolabeled derivatives thereof which are both useful as theranostics of a number of pathologies.

  本发明涉及一种新型杂环化合物，这些化合物是环氧合酶-1（COX-1）的有效和选择性抑制剂，以及它们的放射标记衍生物，这些衍生物既可用作多种病理病变的诊疗药物。
• Isoxazole derivatives and salts thereof
  申请人：Taiho Pharmaceutical Co., Ltd.

  公开号：US05399577A1

  公开（公告）日：1995-03-21

  An isoxazole derivative represented by the general formula (1) or a salt thereof: ##STR1## a method for preparing the same; compositions for inhibiting lipoxygenase and cyclooxygenase comprising an effective amount of the derivative and a pharmaceutically acceptable carrier therefor; and a method for inhibiting lipoxygenase and cyclooxygenase which comprises administering to a patient the derivative.

  一种由一般式（1）表示的异噁唑衍生物或其盐：##STR1## 一种制备该衍生物的方法；包含该衍生物的有效量和药学上可接受的载体的抑制脂肪氧合酶和环氧合酶的组合物；以及一种抑制脂肪氧合酶和环氧合酶的方法，其包括向患者给予该衍生物。
• STYRENE DERIVATIVE AND SALTS THEREOF
  申请人：TAIHO PHARMACEUTICAL CO., LTD.

  公开号：EP0623603A1

  公开（公告）日：1994-11-09

  A styrene derivative represented by general formula (1), a salt thereof, a process for producing the same, lipoxygenase and cyclo-oxygenase inhibitors each containing an effective dose of the derivative and a pharmaceutical carrier, and a method of inhibiting lipoxygenase and cyclo-oxygenase by administering the derivative R₁ and R₂ may be the same or different from each other and each represents hydrogen, lower alkoxy, halogen or lower alkyl ; R₃s may be the same or different from each other and each represents hydroxy, lower alkoxy, lower alkyl, lower alkoxycarbonyloxy, lower acyloxy, a di(lower alkyl) phosphate residue or an optionally protected amino acid residue ; l represents an integer of 0 to 5 ; m represents an integer of 0 to 5 ; X represents a single bond or a group represented by the general formula -N(Z)CO- wherein Z represents (CH₂)nA wherein A represents hydrogen, carboxy, di- or mono(lower alkyl) carbamoyl, carbamoyl, lower alkoxycarbonyl, cyano, lower alkoxy, N-acylamino, optionally substituted phenyl, pyridyl or thienyl, and n represents an integer of 0 to 5 ; and Y represents -C(Z')=CH-, -CH=CH- C(Z')=CH- or -C(Z')=CH-H=CH- wherein Z' is the same as Z, provided the case where both of Z and Z' are hydrogen when n is 0 is excluded.

  通式(1)代表的苯乙烯衍生物、其盐、生产该衍生物的工艺、各含有有效剂量该衍生物和药物载体的脂氧合酶和环氧合酶抑制剂，以及通过施用该衍生物来抑制脂氧合酶和环氧合酶的方法 R₁和R₂可以彼此相同或不同，并且各自代表氢、低级烷氧基、卤素或低级烷基；R₃s 可以相同或不同，各自代表羟基、低级烷氧基、低级烷基、低级烷氧基羰基氧基、低级酰氧基、磷酸二（低级烷基）残基或受任选保护的氨基酸残基；l 代表 0 至 5 的整数；m 代表 0 至 5 的整数；X 代表单键或通式 -N(Z)CO- 所代表的基团，其中 Z 代表 (CH₂)nA 其中 A 代表氢、羧基、二或单（低级烷基）氨基甲酰基、氨基羰基、低级烷氧基羰基、氰基、低级烷氧基、N-酰氨基、任选取代的苯基、吡啶基或噻吩基，n 代表 0 至 5 的整数；Y代表-C(Z')=CH-、-CH=CH- C(Z')=CH-或-C(Z')=CH-H=CH-，其中 Z'与 Z 相同，但不包括 n 为 0 时 Z 和 Z'均为氢的情况。
• NOVEL ISOXAZOLE DERIVATIVE AND SALT THEREOF
  申请人：TAIHO PHARMACEUTICAL CO., LTD.

  公开号：EP0633254A1

  公开（公告）日：1995-01-11

  An isoxazole derivative represented by general formula (1), a salt thereof, a process for the production thereof, an inhibitor for lipoxygenase and cyclooxygenase containing an effective dose of the derivative and a pharmaceutical carrier, and a method of inhibiting lipoxygenase and cyclooxygenase by administering the derivative to a patient. In formula (1) R and R' may be the same or different from each other and each represents hydrogen, lower alkyl, lower alkoxy or halogen; m represents 0 to 5; A represents -NH-, -O- or a direct bond; B represents -C(=Z)-NH-, -C(=Z)-(CH=CH)l- or -CH=CH-, wherein Z represents oxygen or sulfur, and 1 represents 0 to 2; X represents nitrogen or carbon; n represents 0 to 3; and Y represents hydroxy, lower alkoxy, lower alkoxycarbonyloxy, etc.; provided that m represents 1 to 5 when A represents -NH-.

  通式(1)代表的异噁唑衍生物、其盐、其生产工艺、含有有效剂量该衍生物和药物载体的脂氧合酶和环氧合酶抑制剂，以及通过向患者施用该衍生物来抑制脂氧合酶和环氧合酶的方法。在式(1)中，R和R'可以彼此相同或不同，各自代表氢、低级烷基、低级烷氧基或卤素；m代表0至5；A代表-NH-、-O-或直接键；B代表-C(=Z)-NH-、-C(=Z)-(CH=CH)l-或-CH=CH-，其中 Z 代表氧或硫，1 代表 0 至 2；X 代表氮或碳；n 代表 0 至 3；Y 代表羟基、低级烷氧基、低级烷氧基羰氧基等。但当 A 代表-NH-时，m 代表 1 至 5。